pharmaphorum

MAY 31, 2023

PM Society’s ‘Securing Market Access to Medicines for England, Ireland, Scotland & Wales’ – part one Mike.Hammerton Wed, 05/31/2023 - 12:45 Bookmark this

97

97

Pharmaceutical Technology

JULY 20, 2023

Ahead of APEC’s "Rare disease vision 2025" deadline, Asian countries are working at different speeds towards improving drug market access.

75

75

pharmaphorum

MAY 6, 2022

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated challenge. Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. The post Deep Dive: Market Access appeared first on.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 1, 2021

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in France. The draft includes simplification of early access to new medicines aiming to make access faster and more attractive to companies. About the author.

Insurance 78

Insurance Labelling 78

pharmaphorum

FEBRUARY 23, 2021

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and what needs reform. The AMNOG (Act on the Reform of the Market for Medicinal Products) was implemented on the 1 January 2011.

Insurance 90

Insurance Medical Records 90

PhRMA

JANUARY 31, 2023

PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine American innovation, biopharmaceutical leadership and more than 4.4 million American jobs.

185

185

PharmExec

JANUARY 26, 2023

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.

52

52

pharmaphorum

APRIL 1, 2022

However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on.

98

98

Pharmacy Times

SEPTEMBER 5, 2023

Manufacturers must find the right balance in drug pricing, so that medications are appealing to both public and private insurers while still remaining profitable throughout their lifecycle.

Insurance 123

Insurance 123

PharmExec

APRIL 7, 2023

Fingerpaint Group further enforces its commitment to the space, marking its second market access acquisition in three years.

52

52

PharmExec

APRIL 18, 2023

German laws, European VBCs, and trends in China, Brazil, and Saudi Arabia are changing the way global market access works.

52

52

pharmaphorum

JUNE 21, 2022

Whether it’s the levelling up agenda, economics, social care and population health management and more, ICSs are front and centre of everything,” Steven Ferguson, head of Market Access UK and Ireland, IQVIA. The post ICSs: improving patient and market access at a local level appeared first on.

52

52

pharmaphorum

JUNE 8, 2022

The move marks the largest expansion of FH to date and allows clients to benefit from integrated offerings spanning policy, access, value, and evidence. The addition of Avalere’s more than 200 advisors deepens FH’s US market presence and diversifies its customer base. We are excited to welcome Avalere to FH.” .

Communication 52

Communication 52

pharmaphorum

MAY 5, 2023

Securing Market Access to Medicines for England, Ireland, Scotland Wales – The Landscape Ahead Mike.Hammerton Fri, 05/05/2023 - 07:20 Bookmark this

52

52

pharmaphorum

AUGUST 17, 2023

War in the Blood: The battle takes shape in the burgeoning European oncology CAR-T market access space Mike.Hammerton Thu, 17/08/2023 - 09:00 Bookmark this

52

52

Pharmafile

FEBRUARY 28, 2023

Published date: 28/02/2023 Summary: Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring rare disease products to market. read more

Specialty Pharmacies 40

Specialty Pharmacies 40

Pharmaceutical Commerce

OCTOBER 5, 2022

Wednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.

52

52

Pharmaceutical Technology

AUGUST 8, 2023

Pricing and reimbursement of pharmaceuticals is changing in Sweden, with prices lower than average as a result of growing cost containment strategies. Here’s what you need to know.

52

52

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. Government partnerships are crucial to accessibility.

Packaging 52

Packaging Compounding FDA Labelling 52

PharmExec

OCTOBER 18, 2022

Commercial Health Insurance may bring more opportunities for market access in China.

Insurance 52

Insurance 52

pharmaphorum

JUNE 12, 2017

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.

52

52

pharmaphorum

FEBRUARY 19, 2021

Ashfield Advisory , part of UDG Healthcare plc, today announced the acquisition of PHMR Limited, a Market Access Consultancy and specialist in Health Economics and Outcomes Research (HEOR). The post UDG Healthcare acquires market access, HEOR specialist, PHMR Limited as Ashfield Advisory appeared first on.

52

52

Drug Topics

MARCH 26, 2024

According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.

Compounding 185

Compounding 185

PharmExec

MAY 10, 2023

BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.

116

116

PharmExec

JULY 27, 2022

Using data visualizations to improve access to payers.

96

96

PharmExec

NOVEMBER 14, 2022

The move reflects Fingerpaint Group's commitment to innovate its capabilities as clients' needs evolve.

52

52

PharmExec

APRIL 5, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

STAT

FEBRUARY 14, 2024

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. health care system could lose up to  $133 billion  in savings and leave patients without access to the medicines they need.

FDA 137

FDA 137

PhRMA

MARCH 28, 2023

For example, next month the Medicare Payment Advisory Comission plans to vote on policy proposals that ignore the facts around Medicare Part B, and could harm patient access to both currently marketed and future medicines.

234

234

PharmExec

DECEMBER 11, 2023

Five emerging themes likely to impact pharma in the new year.

52

52

pharmaphorum

APRIL 23, 2024

In an on-site interview at Reuters Pharma Europe in Barcelona, this week’s podcast saw Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discuss revitalising Europe’s pharmaceutical landscape and leveraging legislation for health and competitiveness.

64

64

European Pharmaceutical Review

JANUARY 11, 2024

The European Commission (EC) has granted a marketing authorisation for Uzpruvo ® (AVT04) in Europe, a biosimilar candidate to Stelara ® (ustekinumab). The EU ustekinumab market is worth €2.5 The EU ustekinumab market is worth €2.5 In this region, STADA already has six biosimilars approved in this market.

Immunization 105

Immunization 105

PharmExec

APRIL 23, 2024

Leaders in areas such as drug discovery, clinical development and market access will meet to discuss AI, failing life expectancy, and a new generation of talent.

52

52

pharmaphorum

APRIL 4, 2024

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

98

98

PhRMA

MARCH 20, 2023

trade policies that expand market access, protect American intellectual property (IP) rights and address unfair trade barriers abroad. International Trade Commission highlight that U.S. biopharmaceutical exports support high-wage manufacturing jobs, innovation and investment across the U.S.

200

200

PhRMA

MARCH 30, 2023

Between Congress, the Medicare Payment Advisory Commission (MedPAC) and the Center for Medicare & Medicaid Innovation (CMMI), there have been a number of policy proposals of late that would change reimbursement for medicines covered by Medicare Part B, some of which may harm patient access to important treatments. Why is it so unique?

202

202

European Pharmaceutical Review

SEPTEMBER 21, 2023

Authors of the report stated that under The Grand Bargain, countries would be required to protect antimicrobials from unnecessary use, contribute towards research and development for new treatments and guarantee that essential antimicrobials can be accessed, particularly in LMICs.

104

104